Arcadia Biosciences Approves 2026 Omnibus Equity Incentive Plan

What Happened

• Arcadia Biosciences, Inc. (RKDA) announced that its stockholders approved the company's 2026 Omnibus Equity Incentive Plan (the "2026 Plan") at the Annual Meeting held on September 10, 2026. The Board had previously approved the 2026 Plan, which became effective upon stockholder approval.
• The 2026 Plan is the successor to the company's 2015 Omnibus Equity Incentive Plan (the "2015 Plan"), which expired and terminated in 2025; awards previously granted under the 2015 Plan remain governed by that expired plan. The Proxy Statement filed August 10, 2026 describes the 2026 Plan, and the full plan and related option agreement forms were filed as exhibits to the 8-K.

Key Details

• Stockholder approval date: September 10, 2026 (Annual Meeting).
• The 2026 Plan became effective upon that stockholder approval.
• The 2015 Plan expired in 2025; prior awards under the 2015 Plan continue to be governed by it.
• Exhibits filed with the 8-K include the 2026 Plan and forms of option agreements (Exhibits 10.1–10.3).

Why It Matters

• Approval of a new omnibus equity plan gives the company authority to grant future stock-based awards (options, restricted stock, etc.) to employees, directors and consultants—tools commonly used for compensation and incentive alignment.
• For investors, new equity awards can affect share count over time (dilution) and will generally increase stock‑based compensation expense when granted; the filing does not disclose share limits or award specifics in the 8-K summary, so consult the full 2026 Plan (Exhibit 10.1) and the company’s Proxy Statement for details on authorized shares, vesting, and dilution impact.